- Home
- OXBR vs LYRA Comparison
OXBR vs LYRA Comparison
Compare OXBR & LYRA Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- OXBR
- LYRA
- Stock Information
- Founded
- OXBR 2013
- LYRA 2005
- Country
- OXBR Cayman Islands
- LYRA United States
- Employees
- OXBR N/A
- LYRA N/A
- Industry
- OXBR Property-Casualty Insurers
- LYRA Medical/Dental Instruments
- Sector
- OXBR Finance
- LYRA Health Care
- Exchange
- OXBR Nasdaq
- LYRA Nasdaq
- Market Cap
- OXBR 12.7M
- LYRA 15.0M
- IPO Year
- OXBR 2014
- LYRA 2020
- Fundamental
- Price
- OXBR $1.75
- LYRA $9.40
- Analyst Decision
- OXBR Strong Buy
- LYRA Buy
- Analyst Count
- OXBR 1
- LYRA 2
- Target Price
- OXBR $5.00
- LYRA $16.00
- AVG Volume (30 Days)
- OXBR 96.7K
- LYRA 1.9M
- Earning Date
- OXBR 08-07-2025
- LYRA 08-13-2025
- Dividend Yield
- OXBR N/A
- LYRA N/A
- EPS Growth
- OXBR N/A
- LYRA N/A
- EPS
- OXBR N/A
- LYRA N/A
- Revenue
- OXBR $1,363,000.00
- LYRA $1,185,000.00
- Revenue This Year
- OXBR $497.99
- LYRA N/A
- Revenue Next Year
- OXBR $42.14
- LYRA $1,286.17
- P/E Ratio
- OXBR N/A
- LYRA N/A
- Revenue Growth
- OXBR N/A
- LYRA N/A
- 52 Week Low
- OXBR $1.27
- LYRA $3.81
- 52 Week High
- OXBR $5.81
- LYRA $37.50
- Technical
- Relative Strength Index (RSI)
- OXBR 57.92
- LYRA 45.31
- Support Level
- OXBR $1.65
- LYRA $10.15
- Resistance Level
- OXBR $1.94
- LYRA $14.88
- Average True Range (ATR)
- OXBR 0.18
- LYRA 2.03
- MACD
- OXBR 0.03
- LYRA -0.67
- Stochastic Oscillator
- OXBR 90.40
- LYRA 0.42
About OXBR Oxbridge Re Holdings Limited
Oxbridge Re Holdings Ltd is a specialty property and casualty reinsurer. It provides reinsurance solutions through its subsidiary. It focuses on underwriting fully collateralized reinsurance contracts for property and casualty insurance companies in the Gulf Coast region of the United States, with an emphasis on Florida. Oxbridge specializes in underwriting medium frequency, high severity risks, where insufficient data exists to analyze effectively the risk/return profile of reinsurance contracts. The company manages its business on the basis of one operating segment, Property and Casualty Reinsurance.
About LYRA Lyra Therapeutics Inc.
Lyra Therapeutics Inc is a clinical-stage therapeutics company focused on the development and commercialization of novel integrated drug and delivery solutions for the localized treatment of patients. The Company's operations and manages its business as a single operating segment which is the business of developing targeted medicines to address ears, nose, and throat, or ENT diseases. Its initial product candidates, LYR-210 and LYR-220, are bioabsorbable polymeric matrices designed to be administered in a brief, non-invasive, in-office procedure and intended to deliver continuous drug therapy to the sinonasal passages for the treatment of chronic rhinosinusitis, or CRS.